Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Darlington

P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

Journal of Thoracic Oncology

English

Related publications

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

P2.01-37 a Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) With Docetaxel in PTS With Previously Treated NSCLC

Journal of Thoracic Oncology

English

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

Journal of Thoracic Oncology

English

P2.06-10 Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress

Journal of Thoracic Oncology

English

OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis

Journal of Thoracic Oncology

English

P2.06-42 AXL, C-Met and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.

Journal of Thoracic Oncology

English

P2.06-15 Malignant Pleural Mesothelioma in Young Adult People in Uganda

Journal of Thoracic Oncology

English

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Journal of Thoracic Oncology

English

Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer

Journal for ImmunoTherapy of Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Darlington

P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

Related publications

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

P2.01-37 a Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) With Docetaxel in PTS With Previously Treated NSCLC

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

P2.06-10 Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress

OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis

P2.06-42 AXL, C-Met and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.

P2.06-15 Malignant Pleural Mesothelioma in Young Adult People in Uganda

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer